Certification Criteria(on) References Standard / Implementation Specification

Add a New Comment

Review comment and Submit

Edit
Comment #1
doc, docx, pdf
Max Size : 10 MB

Comment

CDC Comments on SVAP 2026

For AR Option reporting, we are optionally adding the R4-D4 IG starting in July 2026. Moving to the R4-D4 IG will allow hospitals to send in tests and results of antimicrobial resistance genes. If the final HTI-5 rule isn’t coming out anytime soon, then we should probably submit the R4-D4 IG version to the SVAP process for AR Option reporting. 

HL7 CDA® R2 Implementation Guide: Healthcare Associated Infection (HAI) Reports, Release 4, STU 4 – US Realm

HL7 Standards Product Brief - HL7 CDA® R2 Implementation Guide: Healthcare Associated Infection (HAI) Reports, Release 4, STU 4 - US Realm | HL7 International

The plan was to keep R4-D4 as an optional IG until we could uncouple the IG version from the ONC requirements with HTI-5. As of right now, we have no planned date for when R4-D4 will become required. 

 

 

Update to the NHSN IG Versions for AR Option Reporting

The Centers for Disease Control and Prevention’s National Healthcare Safety Network (NHSN) would like to propose moving to new Implementation Guide Versions for reporting criterion: § 170.315(f)(6) - Transmission to public health agencies — antimicrobial use and resistance reporting. To accommodate additional data elements, CDC has implemented updated versions for the reporting of Antimicrobial Resistance (AR) events (HL7 CDA® R2 Implementation Guide: Healthcare Associated Infection (HAI) Reports, Release 3 - US Realm, December 2020) and  AR summary/denominator data (HL7 CDA® R2 Implementation Guide: Healthcare Associated Infection (HAI) Reports, Release 3, STU 4 - US Realm, March 2020). These versions can be used to report 2022 AR Option data into NHSN.